 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 December 1993 | Volume 119 Issue 11 | Pages 1067-1071
Objective: To assess the efficacy of hydroxychloroquine, 400 mg daily, for rheumatoid arthritis.
Design: Six-month, double-blind, randomized trial.
Setting: Ambulatory referral clinic in a Mexico City, Mexico, teaching hospital.
Patients: A total of 126 patients with early rheumatoid arthritis were randomly assigned to receive hydroxychloroquine, 400 mg/d, or placebo; 121 patients completed the study.
Results: Hydroxychloroquine showed a clinically and statistically significant improvement over placebo in joint score (20% greater mean improvement; 10% more patients improved by >50%); pain (40% greater mean improvement; 19% more patients improved by >50%); grip strength (22% greater mean improvement; 21% more patients improved by >50%); patient global assessment (16% more patients stated they had improved); and physician global assessment (12% more patients were judged to have improved). Side effects were mild, and no patients in the hydroxychloroquine group required discontinuation of therapy. Patient compliance with the study medication was high.
Conclusion: Hydroxychloroquine is moderately effective in early rheumatoid arthritis.
Author and Article Information
From Universidad Nacional Autonoma de Mexico and the Hospital General de Mexico, Mexico City, Mexico; Ottawa General Hospital and the University of Ottawa, Ottawa, Canada.
ARTICLE
Hydroxychloroquine Compared with Placebo in Rheumatoid Arthritis
A Randomized Controlled Trial
Requests for Reprints: Patricia Clark, MD, MSc, Faculty of Medicine, Universidad Nacional Autonoma de Mexico and Hospital General de Mexico, Unidad de Epidemiologia Clinica, Dr. Balmis, 148 Col. Doctores, C.P. 06726, Mexico.
Acknowledgments: The authors thank Dr. Alfonse T. Masi for his useful suggestions and Ms. Diane Gagnon for preparation of the manuscript.
Grant Support: In part by Sanofi-Winthrop Company, Mexico City, Mexico.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Z. Karim, M. A Quinn, R. J Wakefield, A. K Brown, M. J Green, E. M A Hensor, P. G Conaghan, and P. Emery Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approach Ann Rheum Dis, May 1, 2007; 66(5): 690 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C H M van Jaarsveld, J W G Jacobs, M J van der Veen, A A M Blaauw, A A Kruize, D M Hofman, H L M Brus, G A van Albada-Kuipers, A H M Heurkens, E J ter Borg, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial Ann Rheum Dis, June 1, 2000; 59(6): 468 - 477. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. M. Cash and J. H. Klippel Second-Line Drug Therapy for Rheumatoid Arthritis N. Engl. J. Med., May 12, 1994; 330(19): 1368 - 1375. [Full Text]
|
|
Article
